Paclitaxel-Eluting versus Everolimus-Eluting Coronary Stents in Diabetes | Zendy

Upendra Kaul | Zendy; Sripal Bangalore | Zendy; Ashok Seth | Zendy; Priyadarshini Arambam | Zendy; Rajpal K. Abhaichand | Zendy; Tejas Patel | Zendy; Darshan Banker | Zendy; Atul Abhyankar | Zendy; Ajit Mullasari | Zendy; Sanjay Shah | Zendy; Rajneesh Jain | Zendy; Rajendra Kumar Premchand | Zendy; C.G. Bahuleyan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Paclitaxel-Eluting versus Everolimus-Eluting Coronary Stents in Diabetes

Author(s) -

Upendra Kaul,

Sripal Bangalore,

Ashok Seth,

Priyadarshini Arambam,

Rajpal K. Abhaichand,

Tejas Patel,

Darshan Banker,

Atul Abhyankar,

Ajit Mullasari,

Sanjay Shah,

Rajneesh Jain,

Rajendra Kumar Premchand,

C.G. Bahuleyan

Publication year - 2015

Publication title -

new england journal of medicine

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1510188

Subject(s) - medicine , percutaneous coronary intervention , everolimus , stent , conventional pci , myocardial infarction , clinical endpoint , cardiology , coronary artery disease , zotarolimus , drug eluting stent , confidence interval , revascularization , surgery , randomized controlled trial

The choice of drug-eluting stent in the treatment of patients with diabetes mellitus and coronary artery disease who are undergoing percutaneous coronary intervention (PCI) has been debated. Previous studies comparing paclitaxel-eluting stents with stents eluting rapamycin (now called sirolimus) or its analogues (everolimus or zotarolimus) have produced contradictory results, ranging from equivalence between stent types to superiority of everolimus-eluting stents.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research